Literature DB >> 27909343

Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.

J Edelmann1,2, E Tausch1, D A Landau3,4,5,6, S Robrecht7, J Bahlo7, K Fischer7, A M Fink7, J Bloehdorn1, K Holzmann8, S Böttcher9, L Werner10, M Kneba9, J G Gribben2, D S Neuberg10, C J Wu3, M Hallek7, H Döhner1, S Stilgenbauer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27909343      PMCID： PMC5332302          DOI： 10.1038/leu.2016.317

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Authors:  M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

2.  Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.

Authors:  Dan A Landau; Scott L Carter; Petar Stojanov; Aaron McKenna; Kristen Stevenson; Michael S Lawrence; Carrie Sougnez; Chip Stewart; Andrey Sivachenko; Lili Wang; Youzhong Wan; Wandi Zhang; Sachet A Shukla; Alexander Vartanov; Stacey M Fernandes; Gordon Saksena; Kristian Cibulskis; Bethany Tesar; Stacey Gabriel; Nir Hacohen; Matthew Meyerson; Eric S Lander; Donna Neuberg; Jennifer R Brown; Gad Getz; Catherine J Wu
Journal:  Cell       Date:  2013-02-14       Impact factor: 41.582

3.  Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.

Authors:  Peter Ouillette; Kamlai Saiya-Cork; Erlene Seymour; Cheng Li; Kerby Shedden; Sami N Malek
Journal:  Clin Cancer Res       Date:  2013-04-25       Impact factor: 12.531

4.  Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.

Authors:  Sebastian Böttcher; Matthias Ritgen; Kirsten Fischer; Stephan Stilgenbauer; Raymonde M Busch; Günter Fingerle-Rowson; Anna Maria Fink; Andreas Bühler; Thorsten Zenz; Michael Karl Wenger; Myriam Mendila; Clemens-Martin Wendtner; Barbara F Eichhorst; Hartmut Döhner; Michael J Hallek; Michael Kneba
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

5.  TP53 mutation and survival in chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Barbara Eichhorst; Raymonde Busch; Tina Denzel; Sonja Häbe; Dirk Winkler; Andreas Bühler; Jennifer Edelmann; Manuela Bergmann; Georg Hopfinger; Manfred Hensel; Michael Hallek; Hartmut Döhner; Stephan Stilgenbauer
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

Review 6.  Clonal evolution in cancer.

Authors:  Mel Greaves; Carlo C Maley
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

7.  High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations.

Authors:  Jennifer Edelmann; Karlheinz Holzmann; Florian Miller; Dirk Winkler; Andreas Bühler; Thorsten Zenz; Lars Bullinger; Michael W M Kühn; Andreas Gerhardinger; Johannes Bloehdorn; Ina Radtke; Xiaoping Su; Jing Ma; Stanley Pounds; Michael Hallek; Peter Lichter; Jan Korbel; Raymonde Busch; Daniel Mertens; James R Downing; Stephan Stilgenbauer; Hartmut Döhner
Journal:  Blood       Date:  2012-10-09       Impact factor: 22.113

8.  Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome.

Authors:  Giulia Fabbri; Hossein Khiabanian; Antony B Holmes; Jiguang Wang; Monica Messina; Charles G Mullighan; Laura Pasqualucci; Raul Rabadan; Riccardo Dalla-Favera
Journal:  J Exp Med       Date:  2013-10-14       Impact factor: 14.307

9.  Mutations driving CLL and their evolution in progression and relapse.

Authors:  Dan A Landau; Eugen Tausch; Amaro N Taylor-Weiner; Chip Stewart; Johannes G Reiter; Jasmin Bahlo; Sandra Kluth; Ivana Bozic; Mike Lawrence; Sebastian Böttcher; Scott L Carter; Kristian Cibulskis; Daniel Mertens; Carrie L Sougnez; Mara Rosenberg; Julian M Hess; Jennifer Edelmann; Sabrina Kless; Michael Kneba; Matthias Ritgen; Anna Fink; Kirsten Fischer; Stacey Gabriel; Eric S Lander; Martin A Nowak; Hartmut Döhner; Michael Hallek; Donna Neuberg; Gad Getz; Stephan Stilgenbauer; Catherine J Wu
Journal:  Nature       Date:  2015-10-14       Impact factor: 49.962

10.  Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis.

Authors:  L Bassaganyas; S Beà; G Escaramís; C Tornador; I Salaverria; L Zapata; O Drechsel; P G Ferreira; B Rodriguez-Santiago; J M C Tubio; A Navarro; D Martín-García; C López; A Martínez-Trillos; A López-Guillermo; M Gut; S Ossowski; C López-Otín; E Campo; X Estivill
Journal:  Leukemia       Date:  2015-03       Impact factor: 11.528
View more
  8 in total

1.  Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.

Authors:  Franz X Schaub; Varsha Dhankani; Ashton C Berger; Mihir Trivedi; Anne B Richardson; Reid Shaw; Wei Zhao; Xiaoyang Zhang; Andrea Ventura; Yuexin Liu; Donald E Ayer; Peter J Hurlin; Andrew D Cherniack; Robert N Eisenman; Brady Bernard; Carla Grandori
Journal:  Cell Syst       Date:  2018-03-28       Impact factor: 10.304

2.  Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia.

Authors:  Johannes Bloehdorn; Andrejs Braun; Amaro Taylor-Weiner; Billy Michael Chelliah Jebaraj; Sandra Robrecht; Julia Krzykalla; Heng Pan; Adam Giza; Gulnara Akylzhanova; Karlheinz Holzmann; Annika Scheffold; Harvey E Johnston; Ru-Fang Yeh; Tetyana Klymenko; Eugen Tausch; Barbara Eichhorst; Lars Bullinger; Kirsten Fischer; Martin Weisser; Tadeusz Robak; Christof Schneider; John Gribben; Lekh N Dahal; Mathew J Carter; Olivier Elemento; Dan A Landau; Donna S Neuberg; Mark S Cragg; Axel Benner; Michael Hallek; Catherine J Wu; Hartmut Döhner; Stephan Stilgenbauer; Daniel Mertens
Journal:  Nat Commun       Date:  2021-09-13       Impact factor: 17.694

Review 3.  The MYC oncogene - the grand orchestrator of cancer growth and immune evasion.

Authors:  Renumathy Dhanasekaran; Anja Deutzmann; Wadie D Mahauad-Fernandez; Aida S Hansen; Arvin M Gouw; Dean W Felsher
Journal:  Nat Rev Clin Oncol       Date:  2021-09-10       Impact factor: 66.675

4.  New Recurrent Structural Aberrations in the Genome of Chronic Lymphocytic Leukemia Based on Exome-Sequencing Data.

Authors:  Adrián Mosquera Orgueira; Beatriz Antelo Rodríguez; José Ángel Díaz Arias; Marta Sonia González Pérez; José Luis Bello López
Journal:  Front Genet       Date:  2019-09-20       Impact factor: 4.599

5.  Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.

Authors:  Jitka Malcikova; Sarka Pavlova; Barbara Kunt Vonkova; Lenka Radova; Karla Plevova; Jana Kotaskova; Karol Pal; Barbara Dvorackova; Marcela Zenatova; Jakub Hynst; Eva Ondrouskova; Anna Panovska; Yvona Brychtova; Kristyna Zavacka; Boris Tichy; Nikola Tom; Jiri Mayer; Michael Doubek; Sarka Pospisilova
Journal:  Blood       Date:  2021-12-23       Impact factor: 25.476

Review 6.  Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia.

Authors:  Narjis Fatima; Kyle R Crassini; Lauren Thurgood; Yandong Shen; Richard I Christopherson; Bryone Kuss; Stephen P Mulligan; Oliver Giles Best
Journal:  Cancer Drug Resist       Date:  2020-05-11

Review 7.  Impact of Low-Burden TP53 Mutations in the Management of CLL.

Authors:  Gregory Lazarian; Florence Cymbalista; Fanny Baran-Marszak
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

Review 8.  Recent therapeutic advances in chronic lymphocytic leukemia.

Authors:  Prithviraj Bose; Varsha Gandhi
Journal:  F1000Res       Date:  2017-10-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.